Endometrial polyps are a common gynecological condition and are benign lesions in which the endometrium undergoes focal hyperplasia by the continuous action of estrogen. Polyps can be located anywhere in the cervical canal or uterine cavity and are composed of endometrial glandular epithelium and mesenchymal tissue. With the development and popularity of hysteroscopic techniques, transcervical resection of polyp (TCRP) has become the main treatment for endometrial polyps. However, it was found that after TCRP, there is still a possibility of no significant improvement of menstruation and recurrence of polyps. The author followed up 96 patients after TCRP to investigate the efficacy of mafron or progesterone to prevent recurrence of endometrial polyps after surgery. Hysteroscopy clearly diagnosed endometrial polyps and preoperative diagnostic curettage excluded endometrial cancer in 96 patients who were not yet menopausal, all of whom underwent hysteroscopic electrodesis of endometrial polyps with complete follow-up, aged 24-47 years with an average of 35 years. Postoperative menstrual conditions and the number of recurrence cases were followed up and recorded and compared between groups. The 96 postoperative patients with TCRP were randomly divided into 3 groups. In the mafron treatment group, 34 patients were treated with mafron (each tablet contains 30ug of ethinylestradiol + 150ug of deoxyprogesterone) orally for 21 days, and after stopping the drug, the second course of treatment was started on the 5th day of withdrawal bleeding for 3 months. Thirty-two cases in the group treated with progesterone: postoperative patients were given MPA 8mg/d on the 14th day of menstrual cycle for 10 days per cycle for 3 menstrual cycles. In the control group, 30 patients did not take any medication after TCRP, and the general condition, age, auxiliary examination and past history of the three groups were not special and were comparable. Postoperatively, 96 patients were followed up at 1, 3, and 6 months postoperatively for menstruation and vaginal bleeding, and menstrual volume was estimated by scoring method, and menstrual blood loss charts were filled out before and after surgery for menstrual disorders. Transvaginal ultrasonography was performed 3 and 6 months after menstrual cleansing, and hysteroscopy was performed in patients with uneven endometrial echogenicity, hyperechoic masses in the uterine cavity or endometrial thickening on ultrasonography to clarify whether there was recurrence of EMP. Statistical methods were used to analyze the data using SPSS13.0 software, and the recurrence rate as well as menstrual improvement were compared by chi-square test. The postoperative recurrence rate of endometrial polyps and menstrual abnormalities were compared among the three groups, and the postoperative recurrence rate and the proportion of menstrual abnormalities in the control group were higher than those in the mafron treatment group and the antiretroviral treatment group, with statistically significant differences (P<0.05). There was no statistically significant difference between the two treatment groups (P>0.05). With the continuous improvement of clinical diagnosis and treatment, the trend of endometrial polyps found clinically is increasing year by year, and it is reported that nearly 34% of women with abnormal uterine bleeding may have endometrial polyps, the etiology and recurrence of endometrial polyps are not clear, and may be related to inflammatory diseases, endocrine disorders, especially high estrogen levels. Hysteroscopic endometrial polypectomy can remove the endometrial polyp from the root of the polyp under direct microscopic view, and can protect the normal endometrium, avoiding the blindness of the traditional diagnostic scraping and the trauma to the endometrium. The procedure is less invasive, has a quick recovery and is easily accepted by patients, and has become the gold standard procedure for the treatment of endometrial polyps. It is a low-dose estrogen-progestin compound containing 30ug of ethinylestradiol and 150ug of deoxyprogesterone per tablet, which has high target tissue selectivity, strong affinity with progesterone receptors and 18 times stronger progestin activity than ethinylestradiol, which can counteract the local high estrogen state of endometrium and reduce the recurrence of endometrial polyps; a small amount of estrogen increases endometrial progesterone A small amount of estrogen increases the endometrial progesterone receptors, which has the effect of enhancing progesterone. Meanwhile, mafenone effectively inhibits the secretion of pituitary gonadotropins, which causes FSH and LH to fall in the body and inhibits follicular development and ovulation; the small amount of estrogen contained in mafenone can repair the endometrium and shorten the time of vaginal bleeding. In this study, combined application of momofolone treatment for 3 months after hysteroscopy could effectively improve menstruation and inhibit recurrence of endometrial polyps after surgery. It was found that progesterone may play an important role in stopping the growth and recurrence of polyps. Progesterone induces the proliferating endometrium to change to secretory phase under the effect of high estrogen level, and may periodically retreat and exfoliate, and degenerate the polyps by promoting apoptosis and inhibiting proliferation thus achieving the effect of inhibiting the recurrence of endometrial polyps. In conclusion, the preferred treatment for endometrial polyps is hysteroscopic endometrial polypectomy, and postoperative adjuvant treatment with mafron or progesterone can significantly improve menstruation and reduce postoperative recurrence rate, with better efficacy in clinical application.